Nilotinib Counteracts P-Glycoprotein-Mediated Multidrug Resistance and Synergizes the Antitumoral Effect of Doxorubicin in Soft Tissue Sarcomas-Reference-Cited by-同舟云学术

Nilotinib Counteracts P-Glycoprotein-Mediated Multidrug Resistance and Synergizes the Antitumoral Effect of Doxorubicin in Soft Tissue Sarcomas

Published:2012-05-25 Issue:5 Volume:7 Page:e37735
ISSN:1932-6203
Container-title:PLoS ONE
language:en
Short-container-title:PLoS ONE

Author:

Villar Victor Hugo,Vögler Oliver,Martínez-Serra Jordi,Ramos Rafael,Calabuig-Fariñas Silvia,Gutiérrez Antonio,Barceló Francisca,Martín-Broto Javier,Alemany Regina

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference44 articles.

1. A comparison of adriamycin versus vincristine and adriamycin, and cyclophosphamide versus vincristine, actinomycin-D, and cyclophosphamide for advanced sarcoma.;DA Schoenfeld;Cancer,1982

2. Doxorubicin induced expression of P-glycoprotein in a canine osteosarcoma cell line.;KL Mealey;Cancer Lett,1998

3. Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin.;A Abolhoda;Clin Cancer Res,1999

4. Tyrosine kinase inhibitors as cancer therapy.;GL Nichols;Cancer Invest,2003

5. Role of tyrosine kinase inhibitors in cancer therapy.;A Arora;J Pharmacol Exp Ther,2005

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Germline Genetic Mutations in Adult Patients with Sarcoma: Insight into the Middle East Genetic Landscape;Cancers;2024-04-25

2. Nilotinib exhibits less toxicity than imatinib and influences the immune state by modulating iNOS, p-p38 and p-JNK in LPS/IFN gamma-activated macrophages;Toxicology in Vitro;2024-03

3. When Vessels and Sarcomas Combine: A Review of the Inferior Vena Cava Leiomyosarcoma;Journal of Vascular Diseases;2024-01-08

4. B-cell lymphoma 2 family members and sarcomas: a promising target in a heterogeneous disease;Exploration of Targeted Anti-tumor Therapy;2023-08-24

5. The biology and treatment of leiomyosarcomas;Critical Reviews in Oncology/Hematology;2023-04